€25.66
0.16% day before yesterday
Amsterdam, May 30, 05:39 pm CET
ISIN
BE0003818359
Symbol
GLPG
Sector
Industry

Galapagos Stock price

€25.66
+1.78 7.45% 1M
-0.72 2.73% 6M
-0.86 3.24% YTD
+0.38 1.50% 1Y
-26.94 51.22% 3Y
-154.89 85.79% 5Y
-25.47 49.81% 10Y
Amsterdam, Closing price Fri, May 30 2025
-0.04 0.16%
ISIN
BE0003818359
Symbol
GLPG
Sector
Industry

Key metrics

Market capitalization €1.69b
P/E (TTM) P/E ratio negative
P/S ratio (TTM) P/S ratio 5.73
Revenue growth (TTM) Revenue growth -55.27%
Revenue (TTM) Revenue €295.45m
EBIT (operating result TTM) EBIT €-313.92m
Free Cash Flow (TTM) Free Cash Flow €-317.30m
EPS (TTM) EPS €-2.57
P/E forward negative
P/S forward 6.86
Show more

Is Galapagos a Top Scorer Stock based on the Dividend, High-Growth-Investing or Leverman Strategy?

As a Free StocksGuide user, you can view scores for all 6,782 stocks worldwide.

Galapagos Stock Analysis

Unlock Scores for Free

Analyst Opinions

11 Analysts have issued a Galapagos forecast:

2x Buy
18%
6x Hold
55%
3x Sell
27%

Analyst Opinions

11 Analysts have issued a Galapagos forecast:

Buy
18%
Hold
55%
Sell
27%

Financial data from Galapagos

Income Statement P&L | Balance Sheet | Cash Flow


Quarter TTM Annually
Mar '25
+/-
%
295 295
55% 55%
100%
- Direct Costs 46 46
268% 268%
16%
249 249
31% 31%
84%
- Selling and Administrative Expenses 147 147
41% 41%
50%
- Research and Development Expense 447 447
4% 4%
151%
- -
-
-
- Depreciation and Amortization - -
-
-
EBIT (Operating Income) EBIT -314 -314
93% 93%
-106%
Net Profit -170 -170
151% 151%
-57%

In millions EUR.

Don't miss a Thing! We will send you all news about Galapagos directly to your mailbox free of charge.

If you wish, we will send you an e-mail every morning with news on stocks of your portfolios.

Galapagos Stock News

Neutral
GlobeNewsWire
5 days ago
Mechelen, Belgium;  May 27, 2025, 22:30 CET; regulated information – Galapagos NV (Euronext & NASDAQ: GLPG) announced today that its  Board of Directors created 925,000 subscription rights under a new subscription right plan.
Neutral
GlobeNewsWire
20 days ago
Galapagos to re-evaluate the implementation of the previously announced separation following regulatory and market developments
Positive
Seeking Alpha
about one month ago
Galapagos NV released positive data from the phase 1/2 ATALANTA-1 study using GLPG5101 for the treatment of patients with relapsed/refractory Mantle Cell Lymphoma; 100% ORR/CR was achieved in 8 patients. Updated data from the relapsed/refractory Mantle Cell Lymphoma cohort from the phase 1/2 ATALANTA-1 study is to be presented at a medical conference presentation 2nd half of 2025. The global MC...
More Galapagos News

Company Profile

Galapagos NV is a biotechnology company, which engages in the identification and development of small molecule and antibody therapies. It operates through the Research & Development and Fee-for-Services segment. The company was founded by Onno van de Stolpe, Rudi Pauwels, and Helmuth van Es on June 30, 1999 and is headquartered in Mechelen, Belgium.

Head office Belgium
CEO Henry Gosebruch
Employees 704
Founded 1999
Website www.glpg.com

Register for Free

StocksGuide is the ultimate tool for easily finding, analyzing and tracking stocks. Learn from successful investors and make informed investment decisions. We empower you to become a confident, independent investor.

The Apple stock at a glance with charts, current key metrics, news and stock analyses.
The Best Dividend Stocks in the Dividend Top Scorer list.
Stock Analyses of the Best Stocks Worldwide.
Start building wealth today